Among them, afatinib, an irreversible ERBB family blocker, might be a promising therapeutic choice for HER2-mutant NSCLC with progression after previous chemotherapy or reversible EGFR-TKI treatment (14). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.